Mesoblast targets AMD and retinopathy
Thursday, 10 July, 2008
Mesoblast [ASX: MSB] today released results from its sister company Angioblast's pre-clinical trials into using adult stem cells to treat ocular diseases association with abnormal blood vessels.
Trials involving 42 non-human primates indicates that an injection of Mesoblast's proprietary adult stem cells combined with an anti-VEGF agent were able to reduce the number of leaking blood vessels - a major cause of ocular disease - more effectively than using an anti-VEGF agent alone.
The combination also reduced the number of subsequent anti-VEGF injections required in the primates.
The results of this trial will comprise part of the company's IND application to the US FDA.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
